NASDAQ · WALDW

Waldencast PLC

$0.04 +$0.00 (+4.44%) 1D Market open

Key Metrics

$3.65M
Market cap
P/E · TTM
$272.07M
Revenue · TTM
−$229.75M
Net income
EPS · TTM $-2.52
Dividend yield
Free cash flow −$16.25M
Beta · 1Y 0.60
EBITDA · TTM −$214.44M
Gross margin 67.3%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 18.6 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • Jun 1
    The stock moved +35.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Jun 1
  • Apr 27
    From its Feb 5 high, the share price fell 44%.

    Peak close $0.05 on Feb 5; trough close $0.03 on Apr 27. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -44%
  • Apr 27
    The stock moved -30.1% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 27

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap
Enterprise value$109.79M
Shares outstanding
52-wk range$0.02 – $0.07
Avg volume · 20D31.4K
Net cash −$106.14M
Book value / share$5.07
IndustryPerfumes, Cosmetics & Other Toilet Preparations
ExchangeNASDAQ
About Waldencast PLC
IPO dateMay 10, 2021
Employees364

Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S0.01
P/FCF
EV/EBITDA
EV/Sales0.40
Graham №

Profitability

Gross 67.3%
Operating -80.0%
Net -84.4%
FCF -6.0%
ROE / ROIC -40.9% · -36.2%

Financial Health

Current ratio1.70
Quick ratio0.97
Debt / equity0.30
Debt / EBITDA -0.64
Net cash −$106.14M
Working capital$52.40M

Cash Flow · TTM

Operating CF −$12.82M
Capex −$3.43M
Free cash flow −$16.25M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

3 / 9
Weak fundamentals · 3 of 9 signals passing

Altman Z-Score

-1.5
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2025-06-30 · computed by TickerWolf from SEC filings